Peretinoin

Summary

Peretinoin (CHEMBL4303228) is a phase-3 clinical-stage small molecule; indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Chemistry: 302.5 Da · C20H30O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4303228
Name	Peretinoin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	6437836
Molecular formula	C20H30O2
Molecular weight	302.5
InChIKey	UUBHZHZSIKRVIV-KCXSXWJSSA-N

SMILES: CC(=CCC/C(=C/CC/C(=C/C=C/C(=C/C(=O)O)/C)/C)/C)C

IUPAC name: (2E,4E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,4,6,10,14-pentaenoic acid

Also known as: Nik-333, Peretinoin, PERETINOIN

Parent form; salt/anhydrous children: CHEMBL5274150

Patent coverage: 139 distinct patent families (356 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).